CoChat
Sign Up
Cited by 70

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Infliximab-induced liver injury: Clinical phenotypes, autoimmunity and the role of corticosteroid treatment

Björnsson, Helgi Kristinn, Gudbjornsson, Bjorn, Björnsson, Einar Stefan·2022·Journal of Hepatology
DOI 10.1016/j.jhep.2021.08.024
Open this paper in CoChat — free account

Abstract

Background & aims Infliximab has been associated with drug-induced liver injury (DILI), particularly drug-induced autoimmune hepatitis (DIAIH). DIAIH is commonly treated with corticosteroids, but there is limited data on the efficacy of corticosteroids in infliximab-induced DILI. Methods Patients were included for assessment if they had been treated with infliximab between 2009-2020 in Iceland and had developed elevated liver tests. Other specific etiologies of liver enzyme elevations were excluded. Patients treated with corticosteroids were compared to patients not receiving corticosteroids. Results A total of 36 patients with infliximab-induced DILI were identified: median age was 46 years (IQR 32-54) and 28 (78%) were female. Type of liver injury was predominantly hepatocellular (64%). Median peak liver enzymes were: alanine aminotransferase (ALT) 393 (328-695) U/L, aspartate aminotransferase 283 (158-564) U/L, alkaline phosphatase 116 (83-205) U/L, and bilirubin (10-20) 13 μmol/L. A total of 25 (69%) were positive for anti-nuclear antibody and/or had elevated IgG. Corticosteroids were initiated in 17 (47%). Median time from onset of liver injury to peak ALT value was longer in patients treated with corticosteroids, 22 (12-59) vs. 0 (0-3) days (p = 0.001). Time from peak ALT to normalization of liver enzymes was 45 days in the corticosteroid group vs. 77 days in others (p = 0.062). Corticosteroids were tapered in all patients, with no cases of relapse during the follow-up…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2021.08.024

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 23

  1. Ostapowicz, 2002, Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States, Ann Intern Med., 137, 947, 10.7326/0003-4819-137-12-200212170-00007 · DOI · Paper page
  2. Ghabril, 2013, Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases, Clin Gastroenterol Hepatol, 11, 558, 10.1016/j.cgh.2012.12.025 · DOI
  3. Bjornsson, 2015, Risk of drug-induced liver injury from tumor necrosis factor antagonists, Clin Gastroenterol Hepatol, 13, 602, 10.1016/j.cgh.2014.07.062 · DOI · Paper page
  4. Bjornsson, 2017, Drug-induced autoimmune hepatitis: response to corticosteroids and lack of relapse after cessation of steroids, Clin Gastroenterol Hepatol, 15, 1635, 10.1016/j.cgh.2017.05.027 · DOI · Paper page
  5. de Boer, 2017, Features of autoimmune hepatitis in patients with drug-induced liver injury, Clin Gastroenterol Hepatol, 15, 103, 10.1016/j.cgh.2016.05.043 · DOI · Paper page
  6. De Boer, 2016, Reply, Clin Gastroenterol Hepatol, 14, 1845, 10.1016/j.cgh.2016.08.011 · DOI
  7. Kok, 2018, Acute liver failure from tumor necrosis factor-α antagonists: report of four cases and literature review, Dig Dis Sci, 63, 1654, 10.1007/s10620-018-5023-6 · DOI
  8. Shah, 2019, Now you see it, now you do not: a case of infliximab-induced vanishing bile duct syndrome, ACG Case Reports J, 6, 10.14309/crj.0000000000000134 · DOI
  9. Rodrigues, 2015, Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: a single center report of 8 cases, World J Gastroenterol WJG, 21, 7584, 10.3748/wjg.v21.i24.7584 · DOI · Paper page
  10. Colina, 2013, Infliximab-related hepatitis: a case study and literature review, Dig Dis Sci, 58, 3362, 10.1007/s10620-013-2698-6 · DOI
  11. Glintborg, 2014, Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO, Rheumatology, 53, 2100, 10.1093/rheumatology/keu252 · DOI
  12. Aithal, 2011, Case definition and phenotype standardization in drug-induced liver injury, Clin Pharmacol Ther, 89, 806, 10.1038/clpt.2011.58 · DOI
  13. Eggertsson, 2017, Graphtyper enables population-scale genotyping using pangenome graphs, Nat Genet, 49, 1654, 10.1038/ng.3964 · DOI
  14. Bruno, 2020, HLA associations with infliximab-induced liver injury, Pharmacogenomics J, 10.1038/s41397-020-0159-0 · DOI
  15. Bjornsson, 2016, Categorization of drugs implicated in causing liver injury: critical assessment based on published case reports, Hepatology, 63, 590, 10.1002/hep.28323 · DOI · Paper page
  16. Vollmer, 2020, Characterization of auto-immune hepatitis associated with the use of anti-TNFα agents: an analysis of 389 cases in VigiBase, Autoimmun Rev, 19, 102460, 10.1016/j.autrev.2020.102460 · DOI
  17. van Gerven, 2013, Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission, J Hepatol, 58, 141, 10.1016/j.jhep.2012.09.009 · DOI
  18. Gonnet-Gracia, 2008, Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-a blockers, Clin Exp Rheumatol, 26, 401
  19. Hennes, 2008, Simplified criteria for the diagnosis of autoimmune hepatitis, Hepatology, 48, 169, 10.1002/hep.22322 · DOI · Paper page
  20. Suzuki, 2011, The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury, Hepatology, 54, 931, 10.1002/hep.24481 · DOI
  21. Björnsson, 2011, Patients with typical laboratory features of autoimmune hepatitis rarely need a liver biopsy for diagnosis, Clin Gastroenterol Hepatol, 9, 57, 10.1016/j.cgh.2010.07.016 · DOI
  22. Kaliyaperumal, 2018, Pharmacogenomics of drug-induced liver injury (DILI): molecular biology to clinical applications, J Hepatol, 69, 948, 10.1016/j.jhep.2018.05.013 · DOI
  23. Nicoletti, 2017, Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study, Gastroenterology, 152, 1078, 10.1053/j.gastro.2016.12.016 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Björnsson, H. K., Gudbjornsson, B., & Björnsson, E. S.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2022-01
Volume
76
Issue
1
Pages
86-92
ISSN
0168-8278
DOI
10.1016/j.jhep.2021.08.024
Cited by
70
References
4
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review